The first product to reach the clinic will be ACCelerate™, a urine test that discriminates between benign and malignant adrenal tumours, found in 5% of people undergoing a chest or abdomen scan, to identify which patients with Adrenocortical Carcinoma (ACC) actually need surgery. It combines a unique panel of biomarkers with a machine learning algorithm trained on retrospective data, and has already been validated prospectively in a multi-centre study, showing it to be up to four times more accurate than scans alone.
Alongside ACCelerate™, the team is developing the world’s first stratification test for Polyendocrine Metabolic Ovarian Syndrome (PMOS) – a blood test paired with a machine learning algorithm designed for use in primary care to identify which PMOS subgroup a patient falls into and stratify their risk of related conditions like type 2 diabetes and hypertension.